Pharmacological or genetic orexin1 receptor inhibition attenuates MK-801 induced glutamate release in mouse cortex
| Autor: | Tamara Berdyyeva, Christine Dugovic, Timothy W. Lovenberg, Leah Aluisio, Brock T. Shireman, James R Shoblock, Volha Tryputsen, Pascal Bonaventure, Ian Fraser |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
orexin 1 receptor
medicine.medical_specialty glutamate AMPA receptor Pharmacology biosensor lcsh:RC321-571 Internal medicine Medicine Original Research Article lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry MK-801 business.industry Metabotropic glutamate receptor 5 General Neuroscience Metabotropic glutamate receptor 7 Metabotropic glutamate receptor 6 Endocrinology cortex orexin Metabotropic glutamate receptor NMDA receptor Metabotropic glutamate receptor 1 Metabotropic glutamate receptor 2 business |
| Zdroj: | Frontiers in Neuroscience Frontiers in Neuroscience, Vol 8 (2014) |
| ISSN: | 1662-4548 |
| Popis: | The orexin/hypocretin neuropeptides are produced by a cluster of neurons within the lateral posterior hypothalamus and participate in neuronal regulation by activating their receptors (OX1 and OX2 receptors). The orexin system projects widely through the brain and functions as an interface between multiple regulatory systems including wakefulness, energy balance, stress, reward and emotion. Recent studies have demonstrated that orexins and glutamate interact at the synaptic level and that orexins facilitate glutamate actions. We tested the hypothesis that orexins modulate glutamate signaling via OX1 receptors by monitoring levels of glutamate in frontal cortex of freely moving mice using enzyme coated biosensors under inhibited OX1 receptor conditions. MK-801, an NMDA receptor antagonist, was administered subcutaneously (0.178 mg/kg) to indirectly disinhibit pyramidal neurons and therefore increase cortical glutamate release. In wild-type mice, pretreatment with the OX1 receptor antagonist GSK-1059865 (10 mg/kg S.C.) which had no effect by itself, significantly attenuated the cortical glutamate release elicited by MK-801. OX1 receptor knockout mice had a blunted glutamate release response to MK-801 and exhibited about half of the glutamate release observed in wild-type mice in agreement with the data obtained with transient blockade of OX1 receptors. These results indicate that pharmacological (transient) or genetic (permanent) inhibition of the OX1 receptor similarly interfere with glutamatergic function in the cortex. Selectively targeting the OX1 receptor with an antagonist may normalize hyperglutamatergic states and thus may represent a novel therapeutic strategy for the treatment of various psychiatric disorders associated with hyperactive states. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|